Phase 2 Brain Cancer Trial, Recruiting NCT07093814 Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT07093814
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part, have been fully informed about the study, and are happy to follow all the trial steps
  • You are between 18 and 70 years old (inclusive) at the time of signing the consent form
  • You have been diagnosed with glioblastoma (a type of brain tumour) that has come back or continued to grow
  • Your general health and ability to carry out daily activities meets a minimum score on a standard scale, as measured within the 28 days before starting treatment (confirm with trial site)
  • Your doctors expect you to live for at least 3 more months
  • Your organs (such as liver, kidneys, etc.) are working well enough to take part
  • If you are a woman who could become pregnant, you must have a negative blood pregnancy test within 7 days before starting treatment
  • If you could father or become pregnant, you agree to use effective contraception from signing the consent form until at least 90 days after your last dose

Who may not be able to join:

  • Your cancer has spread to parts of the body outside the brain
  • You have previously had treatment using oncolytic viruses (viruses used to fight cancer) or gene therapy
  • You have taken part in another clinical trial using an unlisted experimental drug or device within the 4 weeks before starting this trial
  • You are known to be allergic to any ingredient in the trial drug (VRT106)
  • You are unable to have an MRI scan of your head
  • You are currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Chengcheng Guo, Sun Yat-Sen University Cancer Center

Phone: 020-87343990

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Guangzhou Virotech Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
2 September 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Evaluate the safety and tolerability of escalating doses of VRT106 in Patients with recurrent/progressive glioblastoma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov